Different from previous relevant studies, we reported the important role of STAT3 signaling in the antitumor activity of cinobufagin, and proposed the potential of cinobufagin to serve as a safe and effective inhibitor of STAT3 for NSCLC therapy. Here, STAT3 is linked to non-small cell lung carcinoma.